Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENALVax-2: DC Vaccine + HD-IL2 + Radiotherapy in Metastatic RCC
NCT03226236Phase 2Withdrawn
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Mar 2016
- Primary completion
- Mar 2019
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous dendritic cell vaccine in renal cell carcinoma (RCC), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Planned start Mar 2016; status: withdrawn.
02
Drugs
autologous dendritic cell vaccine
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03226236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03226236.